Best Fit Health/Biotechnology Funds ETFs
U.S. News evaluated 29 Health/Biotechnology Funds ETFs and 14 make our Best Fit list. Our list highlights the best passively managed funds for long-term investors. Rankings are assigned based on comparisons with Best Fit funds in this category.
| Best Fit Scorecard | |
|---|---|
| Costs | Typical |
| Tracking Error | Excellent |
| Bid/Ask Ratio | Good |
| Holdings Diversity | Typical |
Fund Description
The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Pharmaceuticals IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of pharmaceutical companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. pharmaceuticals companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. It is non-diversified.
Fund Snapshot Updated 05.17.2013
| Previous Close | $42.77 | Expense Ratio | 0.60% |
| YTD Return | 24.0% | Avg. 30-Day Volume | 119,281 |
| 1-Year Return | 42.3% | Market Cap | Loading... |
| Bid | $42.81 | Shares Outstanding | 11,650,000 |
| Ask | $42.82 | Dividends | $0.54 |
| Top 10 Holdings | |
|---|---|
| Gilead Sciences Inc (GILD) | 5.82% |
| Amgen Inc (AMGN) | 5.34% |
| Bristol Myers Squibb Co (BMY) | 5.15% |
| Johnson & Johnson (JNJ) | 5.06% |
| Merck & Co Inc New (MRK) | 4.69% |
| Abbott Labs (ABT) | 4.64% |
| Pfizer Inc (PFE) | 4.64% |
| Lilly Eli & Co (LLY) | 4.52% |
| Santarus Inc (SNTS) | 3.96% |
| Actavis Inc (ACT) | 3.60% |
| % of Total Holdings | 47.40% |
